Nuvelo(NUVO) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Nuvelo(NUVO)

NUVO 0.0001000

0.0%

Aug 11 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: idos	9/25/2006 1:27:52 AM
	Read Replies (1) of 140

A very positive view from Zacks: Zacks.com Announces That Nadine Wong Highlights: Nuvelo Sep 22, 2006 (BUSINESS WIRE) -- Nadine Wong, editor of the BioTech Stock Report newsletter, thinks the worst is behind us. Read about a company that she believes will do well, Nuvelo (NASDAQ:NUVO). Click here for the full story exclusively on Zacks.com: at.zacks.com Highlights from the September 20 Featured Expert column by Nadine Wong include: One company Wong and her team think will do well is Nuvelo (NASDAQ:NUVO). The company expects to complete patient enrollment of alfimeprase for both acute peripheral arterial occlusion (NAPA-2) and catheter occlusion (SONOMA-2) in the second half of 2006. Topline Phase III data should be available in late 2006/early 2007 from both trials and presentation of full data at major medical meetings in the first half of 2007. Both programs have the potential to achieve their clinical endpoints. Nuvelo remains on track to begin Phase II trials of alfimeprase for stroke in the second half of 2006 and for deep vein thrombosis in the first half of 2007, both are large unmet medical needs representing a combined $1 billion opportunity.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next